# US 2025/0375440 A1 · Composition and method of treating cancer associated with egfr mutation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375440 A1
- Document ID: US20250375440A1
- Status: Published application
- Kind: A1
- Application number: 19/217,307
- Filed: 2025-05-23
- Published: 2025-12-11
- Earliest claimed: 2018-06-01
- Assignees: BeyondSpring Pharmaceuticals, Inc.
- Applicants: Beyondspring Pharmaceuticals, Inc.
- Inventors: Lan HUANG; George Kenneth LLOYD
- Web page: https://patentgrep.com/patent/US20250375440A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61P 35/00: Antineoplastic agents
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are plinabulin and its use for treating a cancer or tumor characterized by expression of a mutant form of an epidermal growth factor receptor (EGFR) protein, comprising administering plinabulin to a subject in need thereof.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A method of therapeutically treating a cancer, consisting of:
administering an effective amount of plinabulin, or a pharmaceutically acceptable salt thereof, to a human subject in need thereof, wherein the effective amount of plinabulin, or the pharmaceutically acceptable salt thereof, is from about 20 mg/m2 to about 30 mg/m2 of body surface area, and
administering an effective amount of osimertinib, or a pharmaceutically acceptable salt thereof, to the human subject, wherein the effective amount of osimertinib, or the pharmaceutically acceptable salt thereof, is from about 60 mg to about 100 mg per day, wherein the cancer is characterized by expression of a mutant form of an epidermal growth factor receptor (EGFR) protein, and
wherein the cancer is lung cancer.

### Claim 24 (depends on 23)

The method of claim 23, wherein the lung cancer is selected from the group consisting of non-small cell lung cancer and squamous carcinoma of the lung.

### Claim 25 (depends on 23)

The method of claim 23, wherein the mutant form of the EGFR protein comprises mutation(s) at one or more positions selected from the group consisting of G719, L858, L861, T790, T854, D761, exon 19, and exon 20.

### Claim 26 (depends on 25)

The method of claim 25, wherein the mutant form of the EGFR protein comprises the amino acid substitution T790M.

### Claim 27 (depends on 25)

The method of claim 25, wherein the mutant form of the EGFR protein comprises one or more amino acid substitutions selected from the group consisting of G719S, G719C, G719A, L858R, L861Q, T854A, and D761Y.

### Claim 28 (depends on 23)

The method of claim 23, wherein the osimertinib, or the pharmaceutically acceptable salt thereof, is administered prior to, concurrently with, or after the administration of plinabulin.

### Claim 29 (depends on 23)

The method of claim 23, wherein the plinabulin, or the pharmaceutically acceptable salt thereof, and the osimertinib, or the pharmaceutically acceptable salt thereof, are administered on a different schedule.

### Claim 30 (depends on 23)

The method of claim 23, wherein the plinabulin, or the pharmaceutically acceptable salt thereof, and the osimertinib, or the pharmaceutically acceptable salt thereof, are administered on the same schedule.

### Claim 31 (depends on 23)

The method of claim 23, wherein the effective amount of plinabulin, or the pharmaceutically acceptable salt thereof, is about 30 mg/m2 of body surface area.

### Claim 32 (depends on 23)

The method of claim 23, wherein the osimertinib, or the pharmaceutically acceptable salt thereof, is administered orally.

### Claim 33 (depends on 32)

The method of claim 32, wherein the osimertinib, or the pharmaceutically acceptable salt thereof, is administered orally at about 80 mg per day.

### Claim 34

A method of inhibiting progression of a cancer, consisting of:
administering an effective amount of plinabulin, or a pharmaceutically acceptable salt thereof, to a human subject in need thereof, wherein the effective amount of plinabulin, or the pharmaceutically acceptable salt thereof, is from about 20 mg/m2 to about 30 mg/m2 of body surface area, and
administering an effective amount of osimertinib, or a pharmaceutically acceptable salt thereof, to the human subject, wherein the effective amount of osimertinib, or the pharmaceutically acceptable salt thereof, is from about 60 mg to about 100 mg per day, wherein the cancer is characterized by expression of a mutant form of an EGFR protein, and
wherein the cancer is lung cancer.

### Claim 35 (depends on 34)

The method of claim 34, wherein the effective amount of plinabulin, or the pharmaceutically acceptable salt thereof, is about 30 mg/m2 of body surface area.

### Claim 36 (depends on 34)

The method of claim 34, wherein the osimertinib, or the pharmaceutically acceptable salt thereof, is administered orally.

### Claim 37 (depends on 36)

The method of claim 36, wherein the osimertinib, or the pharmaceutically acceptable salt thereof, is administered orally at about 80 mg per day.

### Claim 38

A method of therapeutically treating a cancer, consisting of:
co-administering plinabulin, or a pharmaceutically acceptable salt thereof, and osimertinib, or a pharmaceutically acceptable salt thereof, to a human subject in need thereof,
wherein the effective amount of plinabulin, or the pharmaceutically acceptable salt thereof, is from about 20 mg/m2 to about 30 mg/m2 of body surface area,
wherein the effective amount of osimertinib, or the pharmaceutically acceptable salt thereof, is from about 60 mg to about 100 mg per day,
wherein the cancer is characterized by expression of a mutant form of an epidermal growth factor receptor (EGFR) protein, and
wherein the cancer is lung cancer.

### Claim 39 (depends on 38)

The method of claim 38, wherein the effective amount of plinabulin, or the pharmaceutically acceptable salt thereof, is about 30 mg/m2 of body surface area.

### Claim 40 (depends on 38)

The method of claim 38, wherein the osimertinib, or the pharmaceutically acceptable salt thereof, is administered orally.

### Claim 41 (depends on 40)

The method of claim 40, wherein the osimertinib, or the pharmaceutically acceptable salt thereof, is administered orally at about 80 mg per day.
